Link to this page
Medical Subject Headings
Last uploaded:
March 22, 2026
| Id | http://purl.bioontology.org/ontology/MESH/D000079963
http://purl.bioontology.org/ontology/MESH/D000079963
|
|---|---|
| Preferred Name | Brentuximab Vedotin |
| Definitions |
Immunoconjugate that consists of the chimeric monoclonal anti - CD30 ANTIGEN antibody cAC-10 conjugated to monomethyl auristatin E. It is used for the treatment of LYMPHOMA.
|
| Synonyms |
SGN 35
Adcetris
CAC10 1006
cAC10vcMMAE
SGN35
cAC10 vcMMAE
CAC10-1006
SGN-35
CAC101006
cAC10-vcMMAE
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | Immunoconjugate that consists of the chimeric monoclonal anti - CD30 ANTIGEN antibody cAC-10 conjugated to monomethyl auristatin E. It is used for the treatment of LYMPHOMA. |
|---|---|
| altLabel |
SGN 35
Adcetris
CAC10 1006
cAC10vcMMAE
SGN35
cAC10 vcMMAE
CAC10-1006
SGN-35
CAC101006
cAC10-vcMMAE
See more
See less
|
| prefLabel | Brentuximab Vedotin
|
| Machine permutation | 2020; BRENTUXIMAB VEDOTIN was indexed under IMMUNOCONJUGATES 2010-2019
|
| HN | 2020 (2010)
|
| type | |
| isa | |
| PA |
D000074322
D000922
|
| tui |
T116
T129
T121
|
| TERMUI |
T000949316
T000910160
T767186
T767185
T798081
|
| TH |
FDA SRS (2017)
USAN (19XX)
INN (19XX)
NLM (2010)
NLM (2017)
NLM (2011)
See more
See less
|
| MMR | 20200101
|
| notation | D000079963
|
| Semantic type UMLS property | |
| RR | 914088-09-8
|
| Inverse of AQ |
See more
See less
|
| DX | 20200101
|
| cui |
C3192355
C5200712
C1832035
C4760489
C2973446
|
| DC | 1
|
| MN |
D12.776.124.790.651.114.224.060.469
D12.776.377.715.548.114.224.200.469
D12.776.124.486.485.114.224.060.438
D12.644.456.217
|
| LT | TRD
|
| AQL | AD AE AN BI BL CF CH CL DE EC GE HI IM IP ME PD PH PK PO RE TO TU UL UR
|
| Inverse of RB |
7XL5ISS668
0
|
| MDA | 20181206
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |